Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Mariano Sust"'
Autor:
Richard Langford, Eugene R. Viscusi, Adelaida Morte, Jesús Cebrecos, Mariano Sust, José María Giménez-Arnau, Oscar de Leon-Casasola
Publikováno v:
Drugs in R&D, Vol 24, Iss 2, Pp 239-252 (2024)
Abstract Background and Objectives New acute pain medications are needed that provide effective analgesia while minimizing side effects and opioid exposure. Clinical trials of co-crystal of tramadol-celecoxib (CTC) have demonstrated an improved benef
Externí odkaz:
https://doaj.org/article/19b3c818f9a44197b7fa0da272900cc9
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0136369 (2015)
E-52862 is a Sigma-1 receptor antagonist (S1RA) currently under investigation as a potential analgesic medicine. We successfully applied a concentration-effect model retrospectively to a four-way crossover Phase I single ascending dose study and util
Externí odkaz:
https://doaj.org/article/d43ff0e8a83b454ca9c1b0680555b1e6
Autor:
Richard Langford, Adelaida Morte, Mariano Sust, Jesús Cebrecos, Anna Vaqué, Esther Ortiz, James Fettiplace, Shola Adeyemi, Grzegorz Raba, Liudmila But‐Husaim, Neus Gascón, Carlos Plata‐Salamán
Publikováno v:
European Journal of Pain. 26:2083-2096
STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal of tramadol-celecoxib (CTC)-a first-in-class analgesic co-crystal comprising racemic tramadol hydrochloride and celecoxib in a supramolecular netwo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d18c55b53ac28affc64ca914ab9fede
https://doi.org/10.1002/ejp.2021
https://doi.org/10.1002/ejp.2021
Autor:
Eugene R. Viscusi, Oscar de Leon‐Casasola, Jesús Cebrecos, Adam Jacobs, Adelaida Morte, Esther Ortiz, Mariano Sust, Anna Vaqué, Ira Gottlieb, Stephen Daniels, Joseph S. Gimbel, Derek Muse, Peter Winkle, Michael E. Kuss, Sebastián Videla, Neus Gascón, Carlos Plata‐Salamán
Publikováno v:
Pain practice : the official journal of World Institute of PainREFERENCES.
Celecoxib-tramadol co-crystal (CTC) is a first-in-class analgesic co-crystal of celecoxib and racemic tramadol with an improved pharmacologic profile, conferred by the co-crystal structure, compared with its active constituents administered alone/con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d52c331d4866bad70763dd1cfb83ddb5
https://pubmed.ncbi.nlm.nih.gov/35686380
https://pubmed.ncbi.nlm.nih.gov/35686380
Autor:
Adelaida Morte, Carlos R. Plata-Salamán, Artur Sans, Mounia Lahjou, James D. Carlson, Anna Vaqué, Jesús Cebrecos, Mariano Sust, Gregorio Encina, Neus Gascón
Publikováno v:
Clinical therapeutics. 43(6)
Purpose Celecoxib-tramadol co-crystal (CTC) is a first-in-class co-crystal of celecoxib and racemic tramadol. This Phase 1 bioavailability study compared single-dose pharmacokinetic (PK) parameters of CTC with those of the individual reference produc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e42c6a308e62bf7e5574950563fa424
https://pubmed.ncbi.nlm.nih.gov/34167827
https://pubmed.ncbi.nlm.nih.gov/34167827
Autor:
Artur Sans, Neus Gascón, Gregorio Encina, Eric Sicard, Lluis Soler, Carlos Plata-Salamán, Mariano Sust, Anna Vaqué, Mounia Lahjou, Sebastián Videla, Marisol Escriche
Publikováno v:
British Journal of Clinical Pharmacology. 84:64-78
SummaryAim We compared the pharmacokinetic (PK) profiles of Co-Crystal of Tramadol-Celecoxib (CTC) versus each reference product (alone and in open combination) after single (first dose) and multiple dosing. Methods Healthy adults aged 18–50 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a98e87ff0e992972a035175df3adff9
https://doi.org/10.1111/bcp.13428
https://doi.org/10.1111/bcp.13428
Autor:
Lluis Soler, Artur Sans, Mariano Sust, Sebastián Videla, Neus Gascón, Mounia Lahjou, Anna Vaqué, Carlos Plata-Salamán, Mercedes Encabo, Gregorio Encina, Eric Sicard
Publikováno v:
British Journal of Clinical Pharmacology
Aim Co-Crystal of Tramadol-Celecoxib (CTC) is a novel co-crystal molecule containing two active pharmaceutical ingredients (APIs) under development by Esteve (E-58425) and Mundipharma Research (MR308). This Phase I study compared single-dose pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13f18b5aa5bb25f33e755823b05d30c
https://doi.org/10.1111/bcp.13395
https://doi.org/10.1111/bcp.13395
Publikováno v:
Cell and Gene Therapy Insights. 6:387396
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eefff6096a124255a78056aba85b9b3
https://doi.org/10.18609/cgti.2020.048
https://doi.org/10.18609/cgti.2020.048
Publikováno v:
British Journal of Clinical Pharmacology. 75:103-117
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • A novel and highly selective sigma-1 receptor antagonist (S1RA) provides a new approach for pain management. S1RA has shown activity in animal models of neuropathic pain and potentiation of opioid analgesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ad48bc5cf98ed0d15b49eac85f627c6
https://doi.org/10.1111/j.1365-2125.2012.04333.x
https://doi.org/10.1111/j.1365-2125.2012.04333.x
Publikováno v:
Journal of Bioequivalence & Bioavailability.
In December 2015, the International Conference of Harmonization (ICH) E14 guideline generated guidance on how exposure-response modelling can be used to characterise the potential for a drug to affect cardiac repolarisation and to modulate the QTc in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::179f65caaffb00001bbda7aec8c88259
https://doi.org/10.4172/jbb.1000307
https://doi.org/10.4172/jbb.1000307